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Cardiovascular risk factors (CRF) were widely described as related to dementia. There are very few studies regarding
this association in FTD. The objective of the study was to compare the frequency of CRF in our population with
FTD and controls. 100 consecutive subjects with FTD diagnosis according to Lund-Manchester clinical criteria and
200 controls matched by age and sex were included between January 2003 to February 2007 at the Cognitive
and Behavior Unit of Hospital Italiano de Buenos Aires. Clinical evaluation, laboratory tests, brain images (CT/MRI),
neuropsychological and neuropsychiatric assessment were performed. Multiple regression analysis was performed
to analyze the association in CRF between FTD patients vs. controls. The mean age in FTD was 69.7 ± 0.9 vs.
70.1 ± 0.8 in controls (p 0.12). No difference in gender was observed between cases and controls. No differences
were identified between patients and controls regarding hypertension (HTA) (65% vs. 67,3% p 0.44); dyslipidemia
(57% vs. 54.7% p 0.74); obesity (39% vs. 27.6% p 0.14) and hypothyroidism (26% vs. 17.1% p 0.1). A significant
difference was observed for Diabetes Mellitus (39% vs. 22.6% p 0.001). In our population, Diabetes Mellitus was
associated as an independent risk factor for FTD. To our knowledge this is the first report in which CRF were
evaluated prospectively in FTD patients. More studies are needed to confirm this finding in larger populations.
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Frontotemporal dementia (FTD) is a broad descriptive term
referring to several distinct clinical syndromes characterized
by progressive neurologic deterioration with prominent
behavioral and language impairment [1,2]. There are three
classic clinical syndromes: behavioral variant frontotem-
poral lobar degeneration (bvFTLD), semantic dementia (a
fluent aphasia with loss of word meaning), and progressive
non-fluent aphasia (a disorder typified by effortful, non-
fluent speech). Frontotemporal dementia (FTD) accounts
for 5–15% of all dementia and is the second commonest
cause in the presenile age group [3,4]. About 20–40% of
FTD cases are familial in series from specialist referral
centers [5-8]. Among the FTD syndromes, bvFTLD is the
most heritable, and semantic dementia the least heritable,
perhaps accounting for recent evidence suggesting that a
high proportion of patients with semantic dementia present* Correspondence: angel.golimstok@hospitalitaliano.org.ar
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unless otherwise stated.over the age of 65 years [9]. A knowledge of risk factors for
FTD may provide clues to the underlying pathophysiology.
There is increasing interest in genetic factors that may
predispose to the disease, and five genetic loci for causal
mutations have been identified, all showing 100% pene-
trance. However, approximately 60% of patients with FTD
have no family history of dementia and are considered
to be sporadic cases. Prospective studies evaluating non-
genetic risk factors for this condition are lacking.
A large number of factors have been associated with
increased risk of dementia in general, and cardiovascular
risk factors are the most consistently reported. A history
of diabetes, hypertension, smoking, obesity, and dyslipid-
emia have all been found to increase risk. Although these
risk factors are well studied in Alzheimer’s Disease (AD),
Vascular Dementia (VD) and Lewy Body Disease (LBD)
[10-16], very few reports are found in FTD.
We therefore undertook a case–control study to analyze
the association of cardiovascular risk factors and FTD.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Golimstok et al. Translational Neurodegeneration 2014, 3:13 Page 2 of 6
http://www.translationalneurodegeneration.com/content/3/1/13Methods
Site
This study was conducted at the Italian Hospital Medical
Care Program (IHMCP) in Buenos Aires, Argentina with
approval from the institutional Review Board of the
IHMCP research committee. IHMCP provides compre-
hensive medical and health services to over 150,000
members primarily located in the urban areas around
the Autonomous City of Buenos Aires, Argentina. The
IHMCP population characteristics are closely representa-
tive of the metropolitan population of the Autonomous
City of Buenos Aires, as demonstrated by 2001 census
data in a series of socio-economic categories (Table 1).
The period of the study was conducted from 2003 through
2007. Patients and controls were analyzed after informed
consent was signed. In demented patients, researchers
ensure that patients fully understand and appreciate the
consequences of their participation throughout the course
of the study. When a demented patient was not able to
make informed decisions, the researchers ensured that the
substitute decision maker (a direct family member) made
the choice regarding patient wishes. Patients with de-
mentia and controls were recruited from the member-
ship of the IHMCP, a large prepaid health maintenance
organization model.
Patients
Our study included patients who met Lund and
Manchester criteria [17]. All patients were evaluated
and diagnosed by a trained neurologist. Clinical evaluation,
laboratory tests, brain images (CT/MRI) and neuropsy-
chological-neuropsychiatric assessment were performed.
Routine clinical investigations were conducted to excludeTable 1 Socioeconomic level and ethnic origin of
inhabitants of the Autonomous City of Buenos Aires and
IHMCP affiliates, based on the 2001 Argentinean census
City of Buenos Aires (%) IHMCP (%)
Upper class 10 5
Upper middle class 16 19.4
Middle class 30 37.5
Lower middle class 21 25.6






African American 1 0.5
Mestizos (a) 3 2
IHMCP, Italian Hospital Medical Care Program. (a) Mestizos (Spanish term used
to designate people of mixed European and Amerindian ancestry living in the
region of Latin America).reversible causes of dementia. Patients were excluded if
formal examination showed evidence of any other brain
disorder, physical and/or mental illness that contributed
considerably to the clinical picture. Patient selection was
strictly consecutive and included all prevalent cases in the
center who met previous criteria.
Controls
Controls were matched to patients with FTD by sex, age
and geographic area of residence. For each patient, we
identified two people from the same general practice list
of the same sex and age. If a potential control was ineli-
gible, we approached the next closest in age. Controls
were never duplicated. Records of potential controls were
reviewed by a neurologist to exclude those controls in
which the presence of dementia of any type or any other
neurological disease was suspected before or during the
index year (year of diagnosis of dementia in the matched
case). The list of the entire population from which poten-
tial controls were randomly drawn was provided by the
record database system of the IHMCP epidemiological
center, and control subjects were selected for cases using a
statistical program.
Ascertainment of cardiovascular risk factors
In order to assess and compare the frequency of cardio-
vascular risk factors in our population with FTD and
controls, the medical records obtained during a 4-year
period (1 January 2003 to 28 February 2007) at IHMCP
were examined. We confined the cardiovascular risk
factor assessment to: age, sex, hypertension (HTA) (in
which hypertension was defined as diastolic blood pres-
sure >90 mmHg and systolic blood pressure >140 mmHg.
The diagnosis was based on medical history, current treat-
ment and results of direct measurements performed on
three different occasions during the study), dyslipidemia
(TG ≥ 150 mg/dl. HDL-C < 40 mg/dL for males, < 50 mg/dL
for females and LDL cholesterol >130 mg/dl), obesity
(defined when body mass index, calculated as the ratio
between weight and squared height, was >30 kg/m2.),
osteoporosis and hypothyroidism (TSH >4.5 mU/L) (by
possible association with dyslipidemia). CVRF were con-
sidered according to CAIDE study data [18] and Dia-
betes (DM) (fasting plasma glucose level ≥ 7.0 mmol/l or
126 mg/dl) according to the Rotterdam study [19].
Statistical analyses
Associations for potential cardiovascular risk factors
were assessed with conditional logistic regression ana-
lyses comparing FTD and control subjects. This was
done in order to identify the collection of features that
displayed differences between study groups while con-
trolling for the effects of the others. Stata 10.1 was used
for this analysis.
Table 3 Logistic regression analyses
Variable P OR (95% CI)
DM2 0.001 4.8 (2.1-6.5)
HTN 0.44 1.3 (0.8-2.1)
Obesity 0.14 1.2 (0.6-1.8)
Dyslipidemia 0.74 1.5 (0.5-2.2)
Hypothyroidism 0.10 1.8 (0.9-3.1)
Osteoporosis 0.36 1.3 (0.7-2.5)
DM: Diabetes mellitus, HTN: hypertension.
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of Hospital Italiano de Buenos Aires, Argentina. Informed
consent was obtained from each case and control included.
Results
During the study period, a total of 100 cases and 200
controls were included. The mean age in FTD cases was
69.7 ± 0.9 vs. 70.1 ± 0.8 in controls (p 0.12). A total of
75% of the population was of female sex in controls vs.
68% in cases included. No sex difference was observed
between cases and controls, as was expected . When the
included population from the IHMCP was compared
with the socioeconomic and ethnic origin data from the
City of Buenos Aires, no significant differences were
observed. A total of 65% of cases had hypertension,
39% obesity and 39% fulfil diagnosis criteria for diabetes.
Baseline characteristics of patients included are displayed
in Table 2. When cases and controls were compared, no
association in hypertension (HTN) (65% vs. 67.3% p 0.44),
dyslipidemia (57% vs. 54.7% p 0.74), obesity (39% vs.
27.6% p 0.14) and hypothyroidism (26% vs. 17.1% p 0.1)
were found in the logistic regression analyses performed.
However, we observed significant association in the logis-
tic regression analysis in Diabetes Mellitus type II (DM2)
between cases and controls (39% vs. 22.6% p = 0.001)
(Table 3).
Discussion
In this study, we examined the frequency of 6 possible
risk factors associated with the likelihood of FTD.
Among the CVRF we did not include tobacco, as it was
very difficult to verify the data in our control group re-
cords. A clinical diagnosis of FTD was associated with a
greater likelihood of having a history of DM2. This is a
very significant finding in our population whereas in
Latin America, diabetes is a highly prevalent disease in
over 45 years, with higher percentages of cases than the
rest of the world [20]. In two previous retrospectiveTable 2 Baseline Characteristics of included patients*
Variable Controls Cases
N = 200 N = 100
Female sex n (%) 150 (75) 68 (68)
Mean age (SD), years 70.1 ± 0.8 69.7 ± 0.9
DM2 N (%) 45 (22.6) 39 (39)
HTN N (%) 134 (67.3%) 65 (65%)
Obesity N (%) 55 (27.6%) 39(39%)
Dyslipidemia N (%) 109 (54.7%) 57 (57%)
Hypothyroidism N (%) 34 (17.1) 34 (26)
Osteoporosis N (%) 40 (20.1%) 21 (21%)
*Data shown as baseline descriptive variables. Comparisons between groups
were made by logistic regression analyses.
DM: Diabetes mellitus, HTN: hypertension.case–control studies the prevalence of this antecedent
was higher in patients with FTD, but the multivariate
analysis showed there were no statistically significant
differences [5,21]. The explanation for this association
remains unclear, but several findings from clinical and
experimental research encourage the formulation of
hypotheses about the underlying mechanisms. Previous
prospective, large, population-based cohort studies have
found that diabetes is associated with an increased risk of
cognitive decline and dementia [19,22,23].
The principal finding of these studies was that diabetes
is associated with a 50-100% increase in risk of AD and
of dementia overall and a 100-150% increased risk of vas-
cular dementia. However, limitations in clinical diagnostic
criteria do not allow the confirmation of a differential
effect on dementia subtype [24].
Type 3 diabetes mellitus (DM3) was described as
corresponding to a chronic insulin resistance plus insulin
deficiency state largely confined to the brain that can over-
lap with DM2 [25]. As It has been proposed that DM3
represents a major pathogenic mechanism of AD neuro-
degeneration [25-26], in the last years have been made
several studies demonstrating the biological substrate of
this mechanism [27-29].
As was expected, such studies have not been performed
in FTD because the association with DM has not been
reported so far.
Areas of active research are the direct effects of hyper-
insulinemia and insulin resistance in the brain. Abnor-
mal insulin sensitivity was found to be associated to
deficits in speech production (verbal fluency), reduction
of gray matter volume in the temporal lobe brain regions
related to language function and lower total brain size as
well [23].
As language processing is usually impaired in patients
with FTD [30,31], these findings should be analyzed.
There is evidence that Central Nervous System (CNS)
insulin signaling enhances synaptic long-term potentiation
[32], modulates the action of neurotransmitters involved
in behavior and cognitive processing (e.g., norepinephrine
and dopamine) [33] and attenuates cortisol secretion [34].
Thus, we can infer that more than one mechanism is
involved in the pathophysiology of these changes and that
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tective and neuromodulatory effects of insulin in the CNS
are disrupted. This may be particularly true in FTD
because the process of neurodegeneration takes place in
brain regions with high densities of insulin receptors that
are sensitive to changes in CNS insulin signaling, such as
in the temporal lobes [35]. Analogous findings related
to similar pathologies demonstrating reduced cerebral
glucose metabolic rate in frontal, parietotemporal, and
cingulate brain regions support these concepts [36].
Furthermore, chronic hyperglycemia, the hallmark of
DM has been shown to accelerate formations of advanced
glycation end products (AGEs) that can induce tau hyper-
phosphorylation which, in turn, impairs synapse and mem-
ory through RAGE-mediated GSK-3 activation [37]. Tau
hyperphosphorylation may be an important event in the
process leading to tau intracellular aggregation and neur-
onal cell death in tauopathies that constitute a significant
percentage of cases of FTD [38].
Supporting this concept, it is known that insulin exerts
its effect through a receptor, a heterotetramer (α2β2)
with tyrosine kinase activity in its intracellular portion.
Joining insulin extracellular α subunits induces a change
in the conformation of β subunits, which initiates a series
of phosphorylations and activates, among others, the path
of PI3-K/Akt. Activation of PKB or Akt deactivates glyco-
gen synthase kinase-3 (GSK-3) [39-41].
Another piece of interesting data that may help to
understand the meaning of the association between
DM2 and FTD are the studies reporting brain atrophy in
DM2 patients mainly exhibiting gray and white matter
atrophy in right temporal lobe, and this finding bears
out that DM2 could lead to subtle diabetic brain structural
changes in patients without dementia or macrovascular
complications [42]. This again corroborates findings in
adults with DM2, where prefrontal volume reductions and
global cerebral atrophy have been reported. Patients with
diabetes, both with and without depression, had smaller
total brain gray matter volumes when compared with the
control subjects after controlling for age, intracranial vol-
ume and years of education. This group also had smaller
gray matter volumes in the anterior cingulate and orbito-
frontal regions when compared with the controls after
additionally controlling for total gray matter volume. The
depressed and nondepressed diabetic groups did not differ
in any neuroimaging measure in this series of patients
reported [43].
Another report showed that greater insulin resistance
as indexed by HOMA-IR was associated with an AD-like
pattern of reduced cerebral metabolic rate of glucose in
frontal, temporal-parietal, and cingulate regions in adults
with pre-diabetes or DM2 [36].
Interestingly, a similar pattern of brain regional glucose
metabolism has been recently described in FTD as well[44]. Obesity was reported as related to brain atrophy,
cognitive deficit [45-47] and as a risk factor for other types
of dementia [48]. However, in our study we found no
statistically significant differences between groups in the
multivariate analysis. So, we suggest that obesity was not
an independent risk factor for FTD, in this population. As
in previous reports [21,49], our study showed that the
percentage of hypothyroidism was higher in cases than in
controls, but the difference was not significant in the
multivariate analysis. Mental studies have shown that spli-
cing of juvenile and adult tau mRNA variants is regulated
by thyroid hormone. As shown by the in situ hybridization
experiments, thyroid hormone seems to regulate the levels
of tau mRNA in the cerebellum by changing the rate of
migration of the granule cell. Another effect of this hor-
mone on tau expression is to modify the timing of the
splicing mechanism that during development allows dif-
ferential selection of exons present in the tau gene. It
remains to be determined whether the effects of thyroid
hormone on cell migration and on the splicing mechanism
are related. It is also not clear whether the post-tran-
scriptional effect of thyroid hormone on the splicing
mechanism is direct or, more probably, mediated by
gene expression. It is widely accepted that the cellular
actions of thyroid hormone are mediated by nuclear
receptors that bind to thyroid hormone response elements
associated with target genes and stimulate or inhibit ex-
pression of these genes. The data reported herein suggest
that, at least for the production of various tau protein iso-
forms during brain development, the splicing mechanism
is regulated by thyroid hormone. Even if this effect of
thyroid hormone is indirect it may explain the impairment
in neurite outgrowth induced by thyroid hormone defi-
ciency in the newborn [50]. The cause of one of the most
common syndromes of frontotemporal dementia are the
tauopathies, and thyroid hormone level abnormalities in
frontotemporal dementia were found to be frequent (38%)
in a previous study [51]. As thyroid disorders may be re-
lated to FTD, further studies to elucidate the mechanisms
of this association are needed. The other factors studied
such as hypertension, dyslipidemia and osteoporosis were
not shown to be risk factors for FTD, which is consistent
with results of previous reports. We include osteoporosis
among risk factors because it has been reported previously
that the vitamin D deficiency is a common finding in
dementia [52].
The strength of our study, with a considerable number
of patients and controls, was that patients were fully
studied and followed over time to verify the diagnosis in
their evolution. Unfortunately, we have no pathology of
our cases, and controls were not studied directly but
through examination of medical records. This last limi-
tation prevented us to compare the images and cognitive
scores between the two groups.
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pathology that distinguish between different variants
included in the diagnosis of FTD and that examine other
factors not analyzed in the present study.
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